Aposense seeks to raise $20M from IPO

05/17/2010 | Globes (Israel)

Aposense hopes to raise $20 million from an initial public offering. The company is working to develop personalized drugs for oncology, cardiology and neurology using its programmed cell death technology. Its first major product is its molecular imaging agent for brain cancer, which currently is in a Phase II study and expected to be on the market by 2012.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX